Inhibition of miR-146a Expression and Regulation of Endotoxin Tolerance by Rhesus Theta-Defensin-1.

"Conflicts of Interest M.E.S. is a cofounder of Oryn Therapeutics, LLC, which has licensed theta-defensin technology for therapeutic development. M.E.S. is an equity holder in Oryn Therapeutics but receives no direct or indirect compensation from the company. A.J.O. is an equity holder in Oryn Therapeutics but receives no direct or indirect compensation. Oryn Therapeutics played no role in the design, execution, or analysis of experiments, or in the writing of the manuscript."

"This work was supported by the National Institute of Allergy and Infectious Diseases (R01-AI22931) (MES), National Institutes of Health (R01-AI125141) (MES, AJO), Arthritis Foundation (#5997) (MES), Southern California Clinical and Translational Science Institute (#ULTR000130) (MES), Seth MacFarlane Foundation (MES), University of Southern California Norris Comprehensive Cancer Center, and NIH National Cancer Institute (support grant #P30 CA014089)."